First Time Loading...
E

Everest Medicines Ltd
HKEX:1952

Watchlist Manager
Everest Medicines Ltd
HKEX:1952
Watchlist
Price: 25.55 HKD 2.4% Market Closed
Updated: May 6, 2024

Everest Medicines Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Everest Medicines Ltd
Net Income (Common) Peer Comparison

Comparables:
6160
1801
603392
300122
300896

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
E
Everest Medicines Ltd
HKEX:1952
Net Income (Common)
-¥844.5m
CAGR 3-Years
47%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Net Income (Common)
-¥13.6B
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Net Income (Common)
-¥1B
CAGR 3-Years
-1%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Net Income (Common)
¥1.2B
CAGR 3-Years
23%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Net Income (Common)
¥8.5B
CAGR 3-Years
40%
CAGR 5-Years
47%
CAGR 10-Years
45%
Imeik Technology Development Co Ltd
SZSE:300896
Net Income (Common)
¥1.3B
CAGR 3-Years
61%
CAGR 5-Years
73%
CAGR 10-Years
N/A

See Also

What is Everest Medicines Ltd's Net Income (Common)?
Net Income (Common)
-844.5m CNY

Based on the financial report for Dec 31, 2023, Everest Medicines Ltd's Net Income (Common) amounts to -844.5m CNY.

What is Everest Medicines Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
3%

Over the last year, the Net Income (Common) growth was -241%. The average annual Net Income (Common) growth rates for Everest Medicines Ltd have been 47% over the past three years , 3% over the past five years .